David Gorelick | University of Maryland Baltimore (original) (raw)

Papers by David Gorelick

PubMed, 1991

Self-report and clinical assessment of substance use were compared with urine analysis results in... more Self-report and clinical assessment of substance use were compared with urine analysis results in 56 male patients consecutively admitted for inpatient psychiatric treatment. All subjects received DSM-III-R Axis I diagnosis and were classified into diagnostic groups. Urine samples were tested for cocaine, marijuana, opiates, phencyclidine (PCP), amphetamines, and barbiturates. Thirty-five of the 56 patients (62%) produced urine samples that were positive for at least 1 substance of abuse. Of this group, 15 patients (27% of total sample) denied substance use during the week prior to admission. In addition, the admitting physician did not identify intoxication in 23 of the 35 patients (66%) with positive urines. The admitting physician's assessment matched the patient's answers regarding recent substance use in 79 percent of the patients. This association was especially apparent with the 26 patients who denied recent substance use, all but one of whom received a drug-negative assessment from the admitting physician.

Journal of Health Care for the Poor and Underserved, 1992

American Journal of Drug and Alcohol Abuse, 1992

We studied the self-reported temporal sequence of cocaine-related problems in 45 male predominant... more We studied the self-reported temporal sequence of cocaine-related problems in 45 male predominantly Black (85%), lower SES cocaine addicts undergoing inpatient treatment at a large urban VA psychiatric hospital. Subjects reported recent average use of 2.5 g of cocaine per day for 14 days each month and experiencing a mean of 14 cocaine-related problems. The temporal sequence of cocaine-related problems was roughly consistent with the sequence of alcohol-related problems reported for alcoholics, with the earliest problems being interpersonal (e.g., arguments with others) and the most recent problems the severest (e.g., job loss, marital separation). The cocaine addicts showed a faster progression from first cocaine use to first cocaine-related problems (mean of 3.75 years) than that reported for alcoholics from first drink to first heavy drinking (8-10 years). Cocaine smokers had a faster course (3.4 years) than intranasal users (5.3 years).

Current Pharmaceutical Design, 2017

Annals of Clinical Psychiatry, Mar 1, 1990

ABSTRACT

Future Medicinal Chemistry, Feb 1, 2012

Psychopharmacology, Mar 20, 2009

Journal of cannabis research, Jul 2, 2021

Journal of cannabis research, Jun 7, 2019

American Journal of Drug and Alcohol Abuse, Sep 25, 2015

Journal of Law Medicine & Ethics, 2003

Psychiatric Clinics of North America

Drug and Alcohol Dependence, 2014

s / Drug and Alcohol Dependence 140 (2014) e2–e85 e81 Opioids with lower brain uptake are less re... more s / Drug and Alcohol Dependence 140 (2014) e2–e85 e81 Opioids with lower brain uptake are less recognizable in rat drug discrimination tests and thus potentially less subject to abuse Stephen D. Harrison1, H. Gursahani1, J. Pfeiffer1, K. Gogas1, J. Riggs1, T. Riley1, D. Gauvin2, S. Doberstein1 1 Nektar Therapeutics, San Francisco, CA, United States 2 MPI Research, Inc., Mattawan, MI, United States Aims: Prescription opioids are the mainstay of analgesic therapy, although their abuse is rising to epidemic proportions. A solution to this problemwould be to separate opioid analgesia from abuse potential. Drugs that are readily recognized as opioids are considered more prone to abuse. We have tested whether lowering the rate of brain entry of an opioidwillmake it less recognizable in rat drug discrimination assays. Methods: Various mu-opioid agonists were assessed for different properties: (1) potency by receptor binding and elicitedfunction in vitro; (2) brain-uptake rate relative to an antipyrine control compound by in situ brain perfusion; (3) potential to be recognized as a mu-opioid agonist by rats trained to recognize oxycodone in the drug discrimination assay. Correlations between these parameters were made to establish underlying relationships between them. Results: The rate of brain uptake and potency of mu-opioid agonists both correlate inversely with the minimum discriminable dose (MDD) in the rat drug discrimination assay. The highest MDD was observed for opioids with dramatically reduced brain uptake rates (between 0.01 and 0.1 relative to antipyrine) compared to commercially used opioids (brain uptake rates between 0.5 and 10 relative to antipyrine). Conclusions: Opioid agonists that have a high potency against the mu-opioid receptor and which have a high rate of entry into the brain are more likely to be recognized as a mu-opioid agonists. A low MDD is considered to be reflective of potential abuse liability and consequently opioids with low brain entry rates, and thus higher MDD values, may have less abuse potential. Consequently it may be possible to maintain analgesic efficacy and yet reduce the potential for the abuse, by reducing brain entry rate. Mu-opioid agonists with an engineered reduction in brain uptake rate offer a potential approach to achieving this goal. Financial support: Nektar Therapeutics. http://dx.doi.org/10.1016/j.drugalcdep.2014.02.239 Differences in cannabis withdrawal symptoms between individuals with and without attention deficit hyperactivity disorder Karen Hartwell1,2, E. Chauchard3,4, D.A. Gorelick3, Aimee McRae-Clark1 1 Department of Psychiatry, MUSC, Charleston, SC, United States 2 Ralph H. Johnson VAMC, Charleston, SC, United States 3 Intramural Research Program, NIDA, Bethesda, MD, United States 4 Toulouse University Octogone-CERPP, Toulouse,